Future studies using Akt inhibitors for the treatment of breast cancer should employ Akt inhibitors that target both Akt1 and Akt2 in combination with inhibitors that target additional signaling pathways such as the MAPK signaling pathway. The gene discussed is AKT1; the disease is breast carcinoma.